文献速递糖尿病

阿巴西普用于延缓1期高危亲属中1型糖尿病进展:一项随机双盲对照试验

Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.
PubMed 文献 · Diabetes Care · 2023-01-01

这项2期随机双盲安慰剂对照试验在抗体阳性且血糖正常(NGT)的参与者中评估阿巴西普每月输注12个月能否延缓进展至异常血糖耐量(AGT)或糖尿病。101例接受阿巴西普、111例接受安慰剂,81例达到终点(阿巴西普35例、安慰剂46例),风险比0.702(95%CI 0.452, 1.09;P=0.11),未达统计学显著;阿巴西普组口服葡萄糖耐量试验的C肽反应更高(P<0.03)。

要点

  • 阿巴西普治疗1年未显著延缓高危个体进展至血糖不耐受(HR 0.702;95%CI 0.452, 1.09;P=0.11)。
  • 阿巴西普组口服葡萄糖耐量试验的C肽反应高于安慰剂组(P<0.03)。
  • 阿巴西普降低治疗期间ICOS+ PD1+ Tfh细胞频率(P<0.0001),增加naive CD4+ T细胞,并降低CD4+ Treg频率(P=0.0067)。

核心结论

  • 尽管阿巴西普治疗1年未显著延缓高危个体进展至血糖不耐受,但影响了免疫细胞亚群并保留了胰岛素分泌,提示共刺激阻断可能改变1型糖尿病的进展。

研究设计与样本

  • 2期随机、安慰剂对照、双盲试验,在抗体阳性且血糖正常(NGT)的参与者中每月输注阿巴西普或安慰剂12个月,终点为口服葡萄糖耐量试验评估的异常血糖耐量(AGT)或糖尿病。
  • 共101例接受阿巴西普、111例接受安慰剂。

主要发现

  • 81例达到AGT或1型糖尿病诊断终点,其中阿巴西普组35例、安慰剂组46例(风险比0.702;95%CI 0.452, 1.09;P=0.11)。
  • 阿巴西普组口服葡萄糖耐量试验的C肽反应高于安慰剂组(P<0.03)。
  • 阿巴西普降低治疗期间诱导性T细胞共刺激分子(ICOS)+ PD1+ 滤泡辅助性T(Tfh)细胞频率(P<0.0001),增加naive CD4+ T细胞,并降低CD4+调节性T细胞(Treg)频率(较基线P=0.0067)。
  • 治疗12个月后,ICOS+ Tfh、naive CD4+ T细胞和Treg频率恢复至基线。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Previous studies showed that inhibiting lymphocyte costimulation reduces declining β-cell function in individuals newly diagnosed with type 1 diabetes. We tested whether abatacept would delay or prevent progression of type 1 diabetes from normal glucose tolerance (NGT) to abnormal glucose tolerance (AGT) or to diabetes and the effects of treatment on immune and metabolic responses. RESEARCH DESIGN AND METHODS: We conducted a phase 2, randomized, placebo-controlled, double-masked trial of abatacept in antibody-positive participants with NGT who received monthly abatacept/placebo infusions for 12 months. The end point was AGT or diabetes, assessed by oral glucose tolerance tests. RESULTS: A total of 101 participants received abatacept and 111 placebo. Of these, 81 (35 abatacept and 46 placebo) met the end point of AGT or type 1 diabetes diagnosis (hazard ratio 0.702; 95% CI 0.452, 1.09; P = 0.11) The C-peptide responses to oral glucose tolerance tests were higher in the abatacept arm (P < 0.03). Abatacept reduced the frequency of inducible T-cell costimulatory (ICOS)+ PD1+ T-follicular helper (Tfh) cells during treatment (P < 0.0001), increased naive CD4+ T cells, and also reduced the frequency of CD4+ regulatory T cells (Tregs) from the baseline (P = 0.0067). Twelve months after treatment, the frequency of ICOS+ Tfh, naive CD4+ T cells, and Tregs returned to baseline. CONCLUSIONS: Although abatacept treatment for 1 year did not significantly delay progression to glucose intolerance in at-risk individuals, it impacted immune cell subsets and preserved insulin secretion, suggesting that costimulation blockade may modify progression of type 1 diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Russell WE, Bundy BN, Anderson MS, et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care. 2023. PMID: 36920087. doi:10.2337/dc22-2200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。